NeuroOne Medical Technologies Corporation has promoted Emily Johns to the expanded role of Chief Administrative Officer and General Counsel. Johns, who joined NeuroOne earlier this year as General Counsel, will continue leading legal strategy while assuming additional responsibilities for human resources, compliance, security and risk management across the organization. Dave Rosa, President and CEO of NeuroOne, emphasized Johns' immediate impact since joining the company. "In the short time that Emily has been with NeuroOne she has made impactful contributions to the organization and the future growth of the business," Rosa stated. "We look forward to her future contributions as we continue to scale our business."
The promotion reflects NeuroOne's strategic focus on strengthening operational infrastructure as the company expands its portfolio of neurological treatments. Johns brings extensive experience in public company law, having previously served as a partner at Honigman LLP where she represented numerous life sciences companies, including NeuroOne on transactional work since 2017. "I am honored to step into this role and continue building on the strong foundation our exceptional team has created," Johns said. "As we look ahead, I look forward to strengthening our operations and infrastructure to help bring our life-changing technologies to more people."
NeuroOne develops minimally invasive and high-definition solutions for EEG recording, stimulation and ablation for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other neurological disorders. The company's technologies aim to improve patient outcomes while reducing procedural costs. Additional information about the company's developments can be found at https://www.nmtc1.com. Johns began her legal career at Sullivan & Cromwell LLP, where she represented public companies in securities offerings and mergers and acquisitions transactions. Her educational background includes a J.D. from UCLA School of Law and a bachelor's degree from the University of Michigan.
The executive promotion comes as NeuroOne continues to advance its neurological treatment technologies while maintaining its Nasdaq listing under the symbol NMTC. This organizational development signals the company's commitment to building robust internal systems to support its growth trajectory in the competitive medical technology sector. The expanded role combines legal oversight with administrative functions, creating a unified approach to governance that could enhance operational efficiency as NeuroOne scales its business. This move demonstrates how medical technology companies are increasingly integrating legal and operational leadership to navigate complex regulatory environments while pursuing innovation in neurological treatments that address significant unmet medical needs.
